Virtual Library
Start Your Search
Qing Bu
Author of
-
+
P36 - Pathology - Prognosis (ID 106)
- Event: WCLC 2020
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P36.06 - The Association Between Prognostic Value and Mutations in TGF-β Signaling Pathway in Small Cell Lung Cancer Patients (ID 2177)
00:00 - 00:00 | Presenting Author(s): Qing Bu
- Abstract
Introduction
Small cell lung cancer (SCLC) is a highly aggressive malignancy, which accounts for approximately 10–15% of all lung cancers. Transforming growth factor beta (TGF-β) is a polypeptide member of the transforming growth factor superfamily of cytokines. Few studies addressing the association between disease prognosis and genetic mutations in TGF-β pathway have been reported up to now. Here we investigate the genetic status of TGF-β pathway as a biomarker to predict overall survival (OS) for small cell lung cancer patients.
Methods
We analyzed a cohort of 103 small cell lung cancer samples from cBioPortal database. Overall survival (OS) was defined as the time between the procedure date when the tumor specimen was collected and the date of death or last follow-up. We estimated and compared the survival curves of these two groups using Kaplan-Meier method and log-rank tests. The threshold of statistical significance value was set to 5% (p < 0.05).
Results
Mutations in 9 genes (AR, CREBBP, EP300, ESR1, MYC, RUNX1, SMAD2, SMAD4, TGFBR2) were the most frequent indications in the TGF-β pathway. These genes were found in 30 (n = 30/103, 29.12%) samples with a total of 40 genetic alterations, including variants of synonymous mutations, non-synonymous mutations, splicing mutations, short in-frame insertion and deletion, and short frame shift insertion and deletion. EP300 was most frequently altered gene (n = 15), followed by CREBBP (n = 14), AR (n = 5), ESR1 (n = 3), SMAD4 (n = 2), and RUNX1 (n = 1). Based on the result, patients were divided into the TGF-β and non-TGF-β group. The median OS of the TGF-β group was 12 months (Table 1), which is significantly shorter than the OS of the non-TGF-β group (log-rank test p = 0.0399, Figure 1).
Conclusion
To our best knowledge, this analysis is the first investigation to evaluate the association between prognostic value and mutations in TGF-β pathway in patients with SCLC. Our investigation shows that TGF-β pathway mutations can be used to predict poor prognosis in SCLC patients. This result will be benefited from additional relevant research by using updated analysis in the future.
